Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342795 · ClinicalTrials.gov registry record · Phase 1
Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation
A Phase 1 study of Nontherapeutic, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 520
- Enrollment target
- 2
- Study locations
NCT02342795: Completed Phase 1 study of Nontherapeutic, sponsored by Virginia Commonwealth University.
NCT02342795 is a Phase 1 study of Nontherapeutic that has completed, run by Virginia Commonwealth University. The registered enrollment target is 520 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (767% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342795, a Phase 1 study of Nontherapeutic, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 520 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to use Randomized Controlled Trial (RCT) methods to examine the influence of novel tobacco products on biomarkers of toxicant exposure and disease risk, reports of adverse events, and concurrent use of other tobacco products. In this case, the novel products are one type of electronic cigarette and an imitation cigarette or cigarette substitute.
Primary Outcome
changes in NNAL concentration measured at week 0, week 4, week 12, and week 24
Conditions Studied
Interventions
- OTHER e-cigarette
- OTHER cigarette substitute
Study Locations (2)
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Virginia
- Center for the Study of Tobacco Products - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
What the finished NCT02342795 record still lists
NCT02342795 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (767% higher).
The record links to 1 condition, with Nontherapeutic appearing as the primary indexed condition, and to 2 interventions - of which e-cigarette is the first listed.
NCT02342795 reports a single indexed study location in Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT02342795 about?
NCT02342795 is a clinical study titled "Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation". The purpose of this study is to use Randomized Controlled Trial (RCT) methods to examine the influence of novel tobacco products on biomarkers of toxicant exposure and disease risk, reports of adverse events, and concurrent use of other tobacco products. In this case, the novel products are one type...
What is the current status of trial NCT02342795?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 520 participants. The study started on 2015-06. Estimated completion is 2018-07.
What conditions does trial NCT02342795 study?
This clinical trial studies the following conditions: Nontherapeutic.
What interventions are being tested in trial NCT02342795?
The interventions under investigation include: e-cigarette (OTHER), cigarette substitute (OTHER).
Who is sponsoring clinical trial NCT02342795?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342795 being conducted?
This trial has 2 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02342795's enrollment target sits among peer trials
520 40th of 2000 higher than 1,961 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia